ArticleAmerican journal of epidemiology2022
A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine.
Article in American journal of epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Evaluation of the Safety of Recombinant Zoster Vaccine on Patients with Systemic Lupus Erythematosus in a Tertiary Hospital in Saudi Arabia: A Retrospective Single Centre Study.Mediterranean journal of rheumatology · 2026Article
- Article
- Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal.PharmacoEconomics - open · 2026Article
- Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in US Medicare Adults Age 65 Years or Older.Drug safety · 2026Article
- Comparison of Vaccine Adverse Events Between Zoster Vaccine Live and Recombinant Zoster Vaccine: A Prospective Multicenter Survey.Journal of Korean medical science · 2026Article
- Safety profile of herpes zoster vaccines in the United States: a descriptive and disproportionality analysis of adverse events reported to the vaccine adverse event reporting system (VAERS), 2017-2024.Frontiers in medicine · 2026Article
- Real-world study: Analysis of post-marketing safety for recombinant zoster vaccine in Shandong, China.Human vaccines & immunotherapeutics · 2025Article
- Article
- Review
- Vaccination Strategies in Respiratory Diseases: Recommendation from AIPO-ITS/ETS, SIMIT, SIP/IRS, and SItI.Respiration; international review of thoracic diseases · 2025Review
- Safety of Adjuvanted Recombinant Herpes Zoster Virus Vaccination in Fragile Populations: An Observational Real-Life Study.Vaccines · 2024Article
- Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.Human vaccines & immunotherapeutics · 2023Review
- A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink.Vaccine · 2023Article
- Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink.Vaccine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recombinant herpes zoster vaccine (RZV), approved as a 2-dose series in the United States in October 2017, has proven highly effective and generally safe. However, a small risk of Guillain-Barré syndrome after vaccination was identified after approval, and questions remain about other possible adverse events. This data-mining study assessed RZV safety in the United States using the self-controlled tree-temporal scan statistic, scanning data on thousands of diagnoses recorded during follow-up to detect any statistically unusual temporal clustering of cases within a large hierarchy of diagnoses. IBM MarketScan data on commercially insured persons at least 50 years of age receiving RZV between January 1, 2018, and May 5, 2020, were used, including 56 days of follow-up; 1,014,329 doses were included. Statistically significant clustering was found within a few days of vaccination for unspecified adverse effects, complications, or reactions to immunization or other medical substances/care; fever; unspecified allergy; syncope/collapse; cellulitis; myalgia; and dizziness/giddiness. These findings are consistent with the known safety profile of this and other injected vaccines. No cluster of Guillain-Barré syndrome was detected, possibly due to insufficient sample size. This signal-detection method has now been applied to 5 vaccines, with consistently plausible results, and seems a promising addition to vaccine-safety evaluation methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.